Keros Therapeutics (NASDAQ:KROS) Shares Up 12% – Here’s What Happened

Keros Therapeutics, Inc. (NASDAQ:KROS)’s share price was up 12% on Thursday . The stock traded as high as $20.25 and last traded at $20.2680. Approximately 901,134 shares changed hands during mid-day trading, a decline of 5% from the average daily volume of 948,360 shares. The stock had previously closed at $18.10.

Wall Street Analyst Weigh In

KROS has been the subject of a number of research analyst reports. HC Wainwright lowered their price target on Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a report on Friday, August 8th. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday. Wedbush upped their target price on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Finally, Oppenheimer reissued an “outperform” rating and issued a $27.00 price target (up previously from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Keros Therapeutics has a consensus rating of “Hold” and a consensus price target of $21.38.

Keros Therapeutics Stock Performance

The stock has a market cap of $617.55 million, a P/E ratio of 13.16, a P/E/G ratio of 0.20 and a beta of 0.89. The firm has a 50 day simple moving average of $16.08 and a two-hundred day simple moving average of $15.03.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.93. The business had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $4.22 million. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The company’s revenue was up 3585.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.41) earnings per share. As a group, equities research analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Insider Transactions at Keros Therapeutics

In related news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The SEC filing for this sale provides additional information. 20.60% of the stock is owned by insiders.

Institutional Trading of Keros Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC boosted its holdings in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company’s stock worth $27,000 after purchasing an additional 2,641 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares during the last quarter. Farther Finance Advisors LLC bought a new position in shares of Keros Therapeutics in the 3rd quarter valued at approximately $47,000. SG Americas Securities LLC acquired a new stake in Keros Therapeutics in the 3rd quarter worth approximately $103,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its position in Keros Therapeutics by 29.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock worth $110,000 after purchasing an additional 1,892 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.